Abstract

Exploring Rheumatologist Perspectives on Therapy Options for COVID-19

Author(s): Dimitris Sikivi

The clinical movement of the serious intense respiratory example Covid 2 (SARS-CoV-2) to basic disease is related with a foundational and unrestrained dissident reaction of the instill and versatile exemption with the arrival of a plenty of proinflammatory cytokines selected "cytokine storm". Without even a trace of a powerful treatment, various off-marker specialists from the armamentarium of rheumatology are utilized. Then, according to the point of view of a rheumatologist, we will quibble the ongoing medicinal procedures in fundamentally sick cases with SARS-CoV-2 pneumonia. In this manner, we will quibble the specialists that mean to target viral section and its replication into the host cell and those affixing and focusing on the subversive reaction. Numerous agents have been utilized with promising outcomes in this setting, but not all have received approval from international authorities and institutions. SARS-CoV-2 monoclonal antibodies and remdesivir have been approved for use in the first step (viral entry), while corticosteroids and interleukin-6 inhibitors or Janus kinase inhibitors are currently used in the second step.